Valeant Pharmaceuticals International Financial Analyst Salaries in Wilmington, DE
The average Valeant Pharmaceuticals International Financial Analyst in Wilmington, DE earns an estimated $71,030 annually, which includes an estimated base salary of $66,430 with a $4,600 bonus. Valeant Pharmaceuticals International's Financial Analyst compensation is $16,370 less than the US average for a Financial Analyst. Financial Analyst salaries at Valeant Pharmaceuticals International in Wilmington, DE can range from $66,000 - $75,000.
In Wilmington, DE, The Finance Department at Valeant Pharmaceuticals International earns $14,254 more on average than the Admin Department.
Last updated 2 years ago.
- $66,430
- avg. base
- $4,600
- avg. bonus
Financial Analyst Salaries at Valeant Pharmaceuticals International
In Wilmington, DE, Financial Analysts earn $1,609 more than Financial Analysts, and $22,155 less than Senior Accountants.
Compensation at Valeant Pharmaceuticals International by Department
In Wilmington, DE, The Finance Department averages $14,254 more than the Admin Department, and $13,694 less than the IT Department
Financial Analyst Compensation by Gender (All Companies)
The average female Financial Analyst at companies similar size to Valeant Pharmaceuticals International reported making $93,556, while the average male Financial Analyst at similar sized companies reported making $91,853.
Financial Analyst Compensation by Ethnicity (All Companies)
The average Asian or Pacific Islander Financial Analyst at companies similar size to Valeant Pharmaceuticals International reported making $98,729, while the average Native American Financial Analyst at similar sized companies reported making $60,000.
How Financial Analysts at Valeant Pharmaceuticals International Rate Their Compensation
The majority of Financial Analysts at Valeant Pharmaceuticals International believe they're compensated fairly. The vast majority (80%) of Financial Analysts at Valeant Pharmaceuticals International are satisfied with their benefits. See more compensation ratings at Valeant Pharmaceuticals International
